Joensuu H et al. Proc ASCO 2011;Abstract LBA1.

Slides:

Advertisements

Similar presentations

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

Advertisements

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.

Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.

GIST Research at Fox Chase Cancer Center Margaret von Mehren, MD.

A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Inhibitor Gefitinb in Completely Resected Stage.

Whom to treat and how long to treat after resection of GIST Professor John R Zalcberg Chief Medical Officer & Director, Division of Cancer Medicine Peter.

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation 1 Phase III Randomized, Open-Label, Multicenter Trial (BRIM3) Comparing BRAF Inhibitor.

Comparison of Nilotinib and Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond One Year Larson.

Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)

11 One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial Joensuu H, Eriksson M, Sundby Hall K, et al.

NHL13: A Multicenter, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation Alone in Patients with Aggressive B ‐ Cell Lymphoma.

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results.

Twelve vs. 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO)

An Ongoing Phase 3 Study of Bosutinib (SKI-606) versus Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Gambacorti-Passerini.

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.

Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.

Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Lipton JH.

Byrd JC et al. Proc ASCO 2011;Abstract 6508.

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.

AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.

OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-

Results of a Randomized Phase 2 Study of PD , a Cyclin ‐ Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole vs Letrozole Alone.

Dasatinib Compared to Imatinib in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Twelve- Month Efficacy and Safety.

Time to Secondary Resistance (TSR) After Interruption of Imatinib: Updated Results of the Prospective French Sarcoma Group Randomized Phase III Trial on.

Switching to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase with Suboptimal Cytogenetic Response on Imatinib: Results from the LASOR.

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Idelalisib (GS- 1101) in Combination with Rituximab and/or Bendamustine.

An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

Results from a Randomized Phase III Trial of Decitabine versus Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,

Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.

A cura di Filippo de Marinis

CCO Independent Conference Highlights

Alessandra Gennari, MD PhD

1 Stone RM et al. Proc ASH 2015;Abstract 6.

Palumbo A et al. Proc ASH 2012;Abstract 200.

Attal M et al. Proc ASH 2010;Abstract 310.

Shustov AR et al. Proc ASH 2010;Abstract 961.

Gajria D et al. Proc SABCS 2010;Abstract P

Rosell R et al. Proc ASCO 2011;Abstract 7503.

Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.

Vahdat L et al. Proc SABCS 2012;Abstract P

Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.

Metastatic/Recurrent Gastrointestinal Stromal Tumors (M/R-GIST): Does surgical resection improve survival?

ESPAC-4: Adjuvant Gemcitabine/ Capecitabine Improves 5-Yr Survival vs Gemcitabine Alone in Resected Pancreatic Ductal Carcinoma CCO Independent Conference.

Martinelli G et al. Proc ASH 2015;Abstract 679.

Mateos MV et al. Proc ASH 2013;Abstract 403.

KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Verstovsek S et al. Proc ASH 2011;Abstract 793.

San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.

Goede V et al. Proc ASH 2014;Abstract 3327.

Swain SM et al. Proc SABCS 2012;Abstract P

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

until tumour progression until tumour progression

Cortes JE et al. Proc ASCO 2010;Abstract 6502.

Coiffier B et al. Proc ASH 2010;Abstract 857.

Vitolo U et al. Proc ASH 2011;Abstract 777.

Faderl S et al. Proc ASCO 2011;Abstract 6503.

Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Martin M et al. Proc SABCS 2012;Abstract S1-7.

1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.

Advani RH et al. Proc ASH 2011;Abstract 443.

1Kantarjian HM et al. Lancet Oncol 2011;12:

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma1 Phase 3 Randomized Study of Ipilimumab (IPI) plus Dacarbazine (DTIC) vs DTIC.

Leber B et al. Proc ASH 2013;Abstract 94.

Presentation transcript:

Joensuu H et al. Proc ASCO 2011;Abstract LBA1. Twelve vs 36 Months of Adjuvant Imatinib as Treatment of Operable GIST with a High Risk of Recurrence: Final Results of a Randomized Trial (SSGXVIII/AIO) Joensuu H et al. Proc ASCO 2011;Abstract LBA1.

Background Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the GI tract. Imatinib (IM) inhibits the KIT and PDGFR alpha tyrosine kinases, which are frequently mutated in GIST, and it is effective in the treatment of advanced GIST. The ACOSOG Z9001 trial showed that one year of adjuvant IM improved regression-free survival (RFS) versus placebo. Study hypothesis: Three years of adjuvant IM results in improved RFS compared to one year of IM in patients diagnosed with KIT-positive GIST. Joensuu H et al. Proc ASCO 2011;Abstract LBA1.

SSGXVIII: Phase III Study Design Eligibility KIT-positive GIST High risk of recurrence by modified consensus criteria* Tumor diameter >10 cm or Tumor mitosis count >10/50 HPF† or Tumor rupture spontaneously or at surgery R (1:1) Imatinib for 12 months Follow-up Imatinib for 36 months Follow-up * Fletcher CD et al. Hum Pathol 2002;33:459. † High-power field of the microscope Stratification: R0 resection, no tumor rupture R1 resection or tumor rupture Both groups received IM 400 mg/day orally; KIT and PDGFRA mutation analyzed centrally. Joensuu H et al. Proc ASCO 2011;Abstract LBA1.

Baseline Characteristics 12 months (N = 199) 36 months (N = 198) Median age, years (range) 62 (23-84) 60 (22-81) ECOG performance status 0, % 85 86 Gastric primary tumor, % 49 53 Median tumor size, cm (range) 9 (2-35) 10 (2-40) Median mitosis count, -/50 HPFs 10 (0-250) 8 (0-165) Tumor rupture, % 18 22 GIST gene mutation site, % - KIT exon 9 - KIT exon 11 - KIT exon 13 - PDGFRA (D842V) - Wild type 6 69 2 13 (10) 10 7 71 1 12 (8) 8 Joensuu H et al. Proc ASCO 2011;Abstract LBA1.

SSGXVIII: Recurrence-Free and Overall Survival (ITT)* Imatinib, 12 mo (n = 199) Imatinib, 36 mo (n = 198) Hazard ratio p-value 3-year RFS 60.1% 86.6% 0.46 <0.0001 5-year RFS 47.9% 65.6% 3-year OS 94.0% 96.3% 0.45 0.019 5-year OS 81.7% 92.0% RFS = recurrence-free survival; OS = overall survival * Median follow-up at 54 months Joensuu H et al. Proc ASCO 2011;Abstract LBA1.

Select Adverse Events Anemia 72% 1% 80% Periorbital edema 59% 74% Imatinib 12 months 36 months Any grade Grade 3/4 Anemia 72% 1% 80% Periorbital edema 59% 74% Elevated LDH 43% 0% 60% Fatigue 48% Nausea 45% 2% 51% Diarrhea 44% 54% Leukopenia 35% 47% 3% Muscle cramps 31% 49% LDH = lactate dehydrogenase Joensuu H et al. Proc ASCO 2011;Abstract LBA1.

Author Conclusions Three years of adjuvant IM improves RFS and OS compared to one year of IM in patients who have a high estimated risk of recurrence after surgery. Five-year RFS 65.6% vs 47.9%, respectively. Five-year OS 92.0% vs 81.7%, respectively. Adjuvant IM is relatively well tolerated. Severe adverse events are infrequent. Joensuu H et al. Proc ASCO 2011;Abstract LBA1.

Investigator Commentary: Results of the Randomized Trial of 12 versus 36 Months of Adjuvant Imatinib Therapy for GIST at High Risk of Recurrence This study of adjuvant therapy for high-risk GIST showed that continuing imatinib for 3 years led to a statistically and clinically significant improvement in overall and disease-free survival. These results are quite impressive. What struck me was that somewhere in the 4-to-6 month period after imatinib was stopped in each arm, you begin to observe a worrisome drop-off. The nature of the failure pattern indicates that longer treatment is better, but it also suggests that imatinib is maintaining a population of cells in long-term stasis, rather than eradicating the disease. This begs the question of indefinite therapy. Imatinib is a highly effective agent, and in many ways represents a gold standard of what we desire of targeted therapy. Even though it is well tolerated, in this study it was associated with some side effects which required dose modifications. This needs to be a consideration in the planning of treatment for individual patients. Leonard B Saltz, MD